HER2 polymorphisms and breast cancer in Tunisian women

Genetic Testing and Molecular Biomarkers

Volumn 14, Issue 1, 2010, Pages 29-35

  Kallel, Imen ^a,b   Kharrat, Najla ^a,c   Al Fadhly, Suad ^c   Rebai, Maha ^a   Khabir, Abdelmajid ^b   Boudawara, Tahia Sallemi ^b   Rebaï, Ahmed ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

^c KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; INTRON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHENOTYPE; REMISSION; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; BASE SEQUENCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DINUCLEOTIDE REPEATS; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENES, ERBB-2; HUMANS; INTRONS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUNISIA; YOUNG ADULT;

EID: 76949101193     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2009.0069     Document Type: Article

References (43)

1. Akai J, Kimura A, Hata RI (1999) Transcriptional regulation of the human type I collagen alpha2 (COL1A2) gene by the combination of two dinucleotide repeats. Gene 239:65-73.
2. Akisiki E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76:260-263.
3. Akiyama T, Sudo C, Ogawara H, et al. (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646. (Pubitemid 16095607)
4. Ameyaw MM, Thornton N, McLeod HL (2000) Re: populationbased, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:1947.
5. An HJ, Kim NK, Oh D, et al. (2005) Her2 genotype and breast cancer progression in Korean women. Pathol Int 55:48-52.
6. Bargmann CI, Hung MC, Weinberg RA (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230.
7. Benusiglio PR, Lesueur F, Luccarini C, et al. (2005) Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 7:204-209.
8. Benusiglio PR, Pharoah PD, Smith PL, et al. (2006) HapMapbased study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer 95:1689-1695.
9. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377.
10. Bornstein P, McKay J, Liska DJ, et al. (1988) Interactions between the promoter and first intron are involved in transcriptional control of alpha 1(I) collagen gene expression. Mol Cell Biol 8:4851-4857.
11. Fleishman SJ, Schlessinger J, Ben-Tal N (2002) A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 99:15937-15940.
12. Gregory RK, Powles TJ, Salter J, et al. (2000) Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 59:171-175.
13. Hauptmann M, Sigurdson AJ, Chatterjee N, et al. (2003) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 95:1251-1252.
14. Kalemi TG, Lambropoulos AF, Gueorguiev M, et al. (2004) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57-65.
15. Kamali-Sarvestani E, Talei AR, Merat A (2004) Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215:83-87.
16. Kashi Y, King D, Soller M (1997) Simple sequence repeats as a source of quantitative genetic variation. Trends Genet 13:74-78.
17. Khabir A, Ghorbel A, Daoud J, et al. (2003) Similar BCL-X but different BCL-2 levels in the two age groups of North African nasopharyngeal carcinomas. Cancer Detect Prev 27:250-255.
18. Kharrat N, Al Fadhli S, Rebaï A (2008) Screening and validation of dinucleotide repeats in intron1 of human EGFR gene and its paralog in Her2 gene. J Recept Signal Transduct 28:475-483.
19. Kuraoka K, Matsumura S, Hamai Y, et al. (2003) A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer 107:593-596.
20. Maekawa T, Imamoto F, Merlino GT, et al. (1989) Cooperative function of two separate enhancers of the human epidermal growth factor receptor proto-oncogene. J Biol Chem 264:5488-5494.
21. McKean-Cowdin R, Kolonel LN, Press MF, et al. (2001) Germline HER-2 variant and breast cancer risk by stage of disease. Cancer Res 61:8393-8394.
22. Millikan R, Eaton A, Worley K, et al. (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79:355-364.
23. Montgomery KG, Gertig DM, Baxter SW, et al. (2003) The HER2 I655V polymorphism and risk of breast cancer in women
24. Nelson SE, Gould MN, Hampton JM, et al. (2005) A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7:357-364.
25. Normanno N, De Luca A, Bianco C, et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16.
26. Papadopoulou E, Simopoulos K, Tripsianis G, et al. (2007) Allelic imbalance of HER-2 codon 655 polymorphism among different religious=ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma 54:365-373.
27. Papewalis J, Nikitin AYu, Rajewsky MF (1991) G to A polymorphism at amino acid codon 655 of the human erbB-2=HER2 gene. Nucleic Acids Res 19:5452.
28. Pegram MD, Finn RS, Arzoo K, et al. (1997) The effect of HER-2=neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547.
29. Pinto D, Pereira D, Portela C, et al. (2005) The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 335:1173-1178.
30. Pinto D, Vasconcelos A, Costa S, et al. (2004) HER2 polymorphism and breast cancer risk in Portugal.: Eur J Cancer Prev 13:177-181.
31. Prenzel N, Fischer OM, Streit S, et al. (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31.
32. Puputti M, Sihto H, Isola J, et al. (2006) Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer Genet Cytogenet 167:32-38.
33. Sharma VK, Kumar N, Brahmachari SK, et al. (2007) Abundance of dinucleotide repeats and gene expression are inversely correlated: a role for gene function in addition to intron length. Physiol Genomics 31:96-103.
34. Shigematsu H, Takahashi T, Nomura M, et al. (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646.
35. Sica A, Tan TH, Rice N, et al. (1992) The c-rel protooncogene product c-Rel but not NF-kappa B binds to the intronic region of the human interferongamma gene at a site related to an interferon-stimulable response element. Proc Natl Acad Sci USA 89:1740-1744.
36. Slamon DJ, Clark GM, Wong SG, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2=neu oncogene. Science 235:177-182.
37. Stern DF, Kamps MP, Cao H (1988) Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969-3973.
38. Tommasi S, Fedele V, Crapolicchio A, et al. (2003) ErbB2 and the antimetastatic nm23=NDP kinase in regulating serum induced breast cancer invasion. Int J Mol Med 12:131-134.
39. Wiseman SM, Makretsov N, Nielsen TO, et al. (2005) Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103:1770-1777.
40. Witton CJ, Reeves JR, Going JJ, et al. (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290-297.
41. Xie D, Shu XO, Deng Z, et al. (2000) Population-based, casecontrol study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412-417. (Pubitemid 30154823)
42. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
43. Zubor P,Vojvodova A, Danko J, et al. (2006)HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a populationbased case-control study in Slovakia. Neoplasma 53:49-55.